These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 19131605)
1. Biomedicine. A new view on--and hope for--an old disease. Cahoon L Science; 2009 Jan; 323(5911):203-5. PubMed ID: 19131605 [No Abstract] [Full Text] [Related]
2. Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment. Jozwiak J; Jozwiak S; Oldak M Med Res Rev; 2006 Mar; 26(2):160-80. PubMed ID: 16329102 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis. Paul E; Thiele E N Engl J Med; 2008 Jan; 358(2):190-2. PubMed ID: 18184966 [No Abstract] [Full Text] [Related]
11. Management of epilepsy in tuberous sclerosis complex. Curatolo P; D'Argenzio L; Cerminara C; Bombardieri R Expert Rev Neurother; 2008 Mar; 8(3):457-67. PubMed ID: 18345974 [TBL] [Abstract][Full Text] [Related]
12. [Recent advance in tuberous sclerosis-related genes and their expression]. Liu J; Piao YS; Lu DH Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):210-2. PubMed ID: 20450774 [No Abstract] [Full Text] [Related]
13. Tuberous sclerosis: genes, brain, and behaviour. Curatolo P Dev Med Child Neurol; 2006 Jun; 48(6):404. PubMed ID: 16700926 [No Abstract] [Full Text] [Related]
14. Biomedicine. A discriminating killer. Cahoon L Science; 2009 Jan; 323(5911):204. PubMed ID: 19131606 [No Abstract] [Full Text] [Related]
15. Rare diseases offer insights into autism spectrum disorders. Preliminary laboratory studies suggest new biological targets for intervention. Harv Ment Health Lett; 2009 Apr; 25(10):3. PubMed ID: 19475765 [No Abstract] [Full Text] [Related]
16. [Neuro-encephalic features of tuberous sclerosis complex]. Belfquih H; El Mostarchid B; Akhaddar A; Gazzaz M; Boucetta M Rev Med Interne; 2012 Aug; 33(8):433-8. PubMed ID: 22658530 [TBL] [Abstract][Full Text] [Related]
18. Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis. Bonnet CS; Aldred M; von Ruhland C; Harris R; Sandford R; Cheadle JP Hum Mol Genet; 2009 Jun; 18(12):2166-76. PubMed ID: 19321600 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of mTOR in tuberous sclerosis. Sampson JR Biochem Soc Trans; 2009 Feb; 37(Pt 1):259-64. PubMed ID: 19143643 [TBL] [Abstract][Full Text] [Related]
20. Genotype-phenotype correlations in tuberous sclerosis: who and how to treat. Goh S; Weiss WA Ann Neurol; 2006 Nov; 60(5):505-507. PubMed ID: 17120247 [No Abstract] [Full Text] [Related] [Next] [New Search]